Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Georgia pharmacy policy update Prior Auth…
    Ask Trek AI about this page
    CurrentAmbetter GeorgiaPolicy CP.PHAR.468

    Berotralstat (Orladeyo) and assorted pharmacy prior authorization updates

    Customize your policy alerts

    Sign up for Ambetter Georgia Policy CP.PHAR.468 alerts

    Get alerted when Policy CP.PHAR.468 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers prior authorization, coding, and coverage-related updates for multiple pharmacy policies with a primary heading of Berotralstat (Orladeyo); affects Ambetter Georgia providers requesting pharmacy-covered medications listed in the document.

    Policy Summary
    PayerAmbetter Georgia
    PolicyBerotralstat (Orladeyo) and assorted pharmacy prior authorization updates
    Policy CodePolicy CP.PHAR.468
    Change TypePediatric age extensionHCPCS additions/removalsapproval-duration extensionsprior therapy simplification
    Effective DateFeb 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization for listed pharmacy products and include evidence of prior covalent BTK inhibitor exposure where required (e.g., pirtobrutinib requests).
    SourceLink
    POLICY UPDATE CHANGES

    Updated to reflect pediatric extension down to 2 years of age and added new oral pellet dosage form.

    Removed HCPCS code J1572 (and other specific HCPCS removals noted per policy).

    Added multiple HCPCS code additions across policies (examples: J9256, J0013, J9282, J9326, C9307, Q5160).

    Extended initial approval durations from 6 to 12 months for some maintenance medications and Medicaid/HIM populations.

    For brand Mavenclad requests, added redirection to generic per SDC request.

    numerouspolicies referenced in revision notes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 yearspediatric age extension noted
    12 monthsinitial approval duration
    multipleHCPCS code changes

    Coverage Criteria & Policy-wide Updates

    Policy-wide coverage updates (summary)

    Selected policy-level coverage clarifications and changes

    Pediatric extension: Policies updated to extend pediatric approval down to 2 years of age where applicable.age >= 2 years

    Applied across multiple listed policies per RT4 revision notes

    Initial approval duration extension: For certain maintenance medications and for Medicaid/HIM initial approvals, initial approval duration extended from 6 months to 12 months.initial approval = 12 months

    Examples include retifanlimab (Zynyz) and other maintenance meds as noted in RT4

    Prior therapy simplification example: For pirtobrutinib (Jaypirca) in CLL/SLL, prior therapy requirement simplified to 'Member has received prior treatment with a covalent BTK inhibitor'.prior therapy includes covalent BTK inhibitor

    Per updated prescribing information in RT4

    Use of Collagenase Clostridium Histolyticum (Xiaflex®) for the treatment of Peyronie's Disease is a benefit exclusion for New York Essential Plans and New York Medicaid (including CHIP) and will NOT be authorized per state regulations. Providers should not submit authorization requests for Xiaflex for Peyronie's Disease for members covered under these New York products, as approvals are prohibited by state-specific coverage rules.

    Coding / HCPCS Changes

    HCPCS code changesHCPCS
    J9256HCPCS code added (listed in RT4 for select policy updates)
    J0013HCPCS code added (ophthalmic injection updates)
    J9282HCPCS code added (mitomycin/Prademagene entries)
    J9326HCPCS code added (telisotuzumab vedotin)
    C9307HCPCS code added (linvoseltamab)
    Q5160HCPCS code added (bevacizumab biosimilars)
    J1572HCPCS code removed (example listed in revision notes)
    J0172HCPCS code removed (example listed in revision notes)
    J9999HCPCS code removed (example listed in revision notes)
    C9399HCPCS code removed (example listed in revision notes)
    1–10 of 12
    1/2

    Provider Actions, Prior Authorization & Operational Notes

    Prior Authorization

    Obtain prior authorization for listed pharmacy products; note HCPCS and approval-duration updates

    Multiple pharmacy‑covered products listed in this set require prior authorization. Revision notes across affected policies record HCPCS code additions and removals (examples: added J9256, J0013, J9282, J9326, C9307, Q5160; removed J1572, J0172, J9999, C9399, C9305, C9306) and also extended initial approval durations from 6 to 12 months for certain maintenance medications and Medicaid/HIM populations.

    • Prior authorization is required for the listed pharmacy products identified in the policies referenced in these revision notes.
    • Be aware that HCPCS code lists were updated per RT4 (multiple additions and removals); use the policy-specific code section when submitting PA requests.
    • Some policies extend initial approval duration to 12 months — confirm applicable duration per specific drug policy.
    Step Therapy

    Document prior covalent BTK inhibitor exposure for pirtobrutinib (Jaypirca)

    For pirtobrutinib (Jaypirca) when requested for CLL/SLL, the prior‑therapy requirement has been simplified: the member must have received prior treatment with a covalent BTK inhibitor; initial approval durations were also extended to 12 months for all indications per the RT4 revision.

    Initial Therapy Criteria & Approval Durations

    Initial therapy duration changes

    Examples of initial therapy policy adjustments

    Initial approval duration change: Initial approval periods for certain maintenance medications have been extended from 6 months to 12 months.12 months

    RT4 revision applied to Medicaid/HIM and maintenance therapy policies (e.g., Retifanlimab/Zynyz)

    Step Therapy Requirements

    StepPrior therapy requirementIndication / notes
    1
    Member has received prior treatment with a covalent BTK inhibitor
    Pirtobrutinib (Jaypirca) for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) — prior therapy simplified per updated prescribing information; initial approval duration extended to 12 months for applicable indications

    Key Drug Definitions

    inv-09: Berotralstat (Orladeyo)
    Drug nameBerotralstat (Orladeyo)
    Mechanism of actionPlasma kallikrein inhibitor
    Policy number referencedCP.PHAR.468 (listed in document)
    Revision note applicableUpdated to reflect pediatric extension down to 2 years of age and added new oral pellet dosage form
    Related administrative updateHCPCS code removals noted in revision notes (examples include J1572, J0172)
    inv-10: Aducanumab-avwa (Aduhelm)
    Drug name

    Policy Background & Scope

    This document is a compilation of RT4 revision notes and brief descriptions applied across multiple Ambetter Georgia pharmacy policies. It records administrative and clinical updates including pediatric age extensions (notably extension down to 2 years where applicable), additions and removals of HCPCS codes, and changes to initial approval durations for certain maintenance medications. Revision notes also include state-specific clarifications such as the New York exclusion for Xiaflex in Peyronie's Disease and operational routing instructions (for example, required redirection to generic products in some cases).

    Policy Summary
    PayerAmbetter Georgia
    PolicyBerotralstat (Orladeyo) and assorted pharmacy prior authorization updates
    Policy CodePolicy CP.PHAR.468
    Change TypePediatric age extensionHCPCS additions/removalsapproval-duration extensionsprior therapy simplification
    Effective DateFeb 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization for listed pharmacy products and include evidence of prior covalent BTK inhibitor exposure where required (e.g., pirtobrutinib requests).
    SourceLink
    On This Page
    Coverage Criteria & Policy-wide UpdatesCoding / HCPCS ChangesProvider Actions, Prior Authorization & Operational NotesInitial Therapy Criteria & Approval DurationsStep Therapy RequirementsKey Drug DefinitionsPolicy Background & Scope
    • Document prior exposure to a covalent BTK inhibitor in the member's medication history when requesting pirtobrutinib for CLL/SLL.
    • Verify and record the updated approval duration (12 months) on the authorization request where applicable.
    Documentation Required

    Expect redirection of Mavenclad (brand) requests to generic per SDC

    Requests for brand Cladribine (Mavenclad) will be operationally redirected to the generic formulation per SDC request; submitters should expect routing to the generic product.

    • When initiating a PA for Mavenclad, indicate whether a generic is available — the request will be redirected to the generic as noted in the RT4 revision.
    • Do not submit requests that assume brand‑only coverage when a generic equivalent is available and SDC redirection is in effect.
    Denial Risk

    Do not request Xiaflex for Peyronie's Disease for NY Essential Plans or NY Medicaid/CHIP

    Use of Collagenase Clostridium Histolyticum (Xiaflex) for treatment of Peyronie's Disease is a benefit exclusion and will not be authorized for New York Essential Plans and New York Medicaid (including CHIP); do not submit PA requests for these New York populations.

    • Do not submit prior authorization requests for Xiaflex for Peyronie's Disease for members covered by New York Essential Plans or New York Medicaid (including CHIP); such requests will be denied per state regulations.
    • Confirm the member's plan type and state coverage before initiating any authorization for Xiaflex.
    Aducanumab‑avwa (Aduhelm)
    Class / targetMonoclonal antibody targeting amyloid beta
    Policy number referencedCP.PHAR.468 (listed in document)
    Revision note applicableUpdated to reflect pediatric extension down to 2 years of age and added new oral pellet dosage form
    Associated agents mentionedDocument groups Aducanumab-avwa with other drugs covered in CP.PHAR.468 (e.g., Berotralstat, Cladribine)